# US 2010/0061935 A1 · Methods of using sustained release aminopyridine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0061935 A1
- Document ID: US20100061935A1
- Status: Published application
- Kind: A1
- Application number: 12/557,015
- Filed: 2009-09-10
- Published: 2010-03-11
- Earliest claimed: 2008-09-10
- Assignees: Acorda Therapeutics, Inc.
- Inventors: Andrew R. Blight; Ron Cohen
- Web page: https://patentgrep.com/patent/US20100061935A1

## CPC

- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 38/21: Interferons {[IFN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.

## Claims

### Claim 1

A method of treating multiple sclerosis in a subject comprising administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject, wherein said multiple sclerosis is selected from relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis and progressive-relapsing multiple sclerosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sustained release aminopyridine composition comprises one or both of 3-hydroxy-4-aminopyridine and 3-hydroxy-4-aminopyridine sulfate.

### Claim 3 (depends on 1)

The method of claim 1, wherein twice daily is every 12 hours.

### Claim 4

A method of treating multiple sclerosis in a subject comprising
administering to said subject an immunomodulator; and
administering to said subject to said subject a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily.

### Claim 5 (depends on 4)

The method of claim 4, wherein said immunomodulator is selected from interferons, natalizumab, glatiramer acetate an combinations thereof.

### Claim 6

A method of treating spasticity associated with multiple sclerosis in a subject comprising administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject, wherein the spasticity of said subject is decreased.

### Claim 7

A method of treating multiple sclerosis in a subject comprising
measuring said patient's creatinine clearance; and
administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject if said subject's creatinine clearance is greater than or equal to 30 ml/min.

### Claim 8 (depends on 7)

The method of claim 7, wherein measuring said patient's creatinine clearance occurs prior to initial administration of said sustained release composition comprising 10 milligrams of 4-aminopyridine.

### Claim 9 (depends on 7)

The method of claim 7, wherein measuring said patient's creatinine clearance occurs during a treatment period.

### Claim 10 (depends on 7)

The method of claim 7, wherein administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject is continued unless said subject's creatinine clearance is less than 30 mL/min.

### Claim 11

A method of treating multiple sclerosis multiple sclerosis in a subject comprising
measuring said patient's creatinine clearance; and
administering a sustained release composition comprising 4-aminopyridine, wherein the amount and the frequency of administration to said patient is dependent upon the measured creatinine clearance.

### Claim 12

A method of testing the efficacy of a sustained release composition comprising 4-aminopyridine for treating multiple sclerosis comprising:
assessing potential patients for study, based on particular inclusion and exclusion criteria, excluding patients with creatinine clearance rates below about 30 mL/min;
assigning known portions of patients to placebo and Fampridine-SR groups, unknown to them or an evaluator in a double-blind study for receipt of placebo or Fampridine-SR; and
assessing one or more of walking speed, leg strength, and spasticity over the course of 8 weeks of treatment.

### Claim 13 (depends on 12)

The method of claim 12, wherein creatinine clearance rates are obtained prior to each assessment.

### Claim 14

A method assessing the efficacy of a sustained release composition comprising 4-aminopyridine for treating multiple sclerosis comprising
assigning known portions of a sample of patients with multiple sclerosis to placebo and Fampridine-SR groups, unknown to them or an evaluator in a double-blind study for receipt of placebo or Fampridine-SR; and
assessing one or more of walking speed, leg strength, and spasticity for said patients over the course of treatment;
wherein the size of said sample of patients shall provide about 90% power and a statistical significance level of 0.05 or lower.

### Claim 15 (depends on 14)

The method of claim 14 further comprising assessing potential patients for study based on particular inclusion and exclusion criteria.

### Claim 16 (depends on 15)

The method of claim 15, wherein said exclusion criteria is a creatinine clearance rate below about 30 mL/min.

### Claim 17 (depends on 14)

The method of claim 14, wherein the course of treatment is eight weeks.
